Clinical significance of phospholipid-dependent anti-β2-glycoprotein I(β2-GPI) antibodies in systemic lupus erythematosus

J. Kaburaki, M. Kuwana, M. Yamamoto, S. Kawai, Eiji Matsuura, Y. Ikeda

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We investigated the clinical significance of IgG phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies in patients with SLE. The study population consisted of 140 patients with SLE. Sera were examined for IgG phospholipid-dependent anti-β2-GPI antibodies by ELISA. IgG phospholipid-dependent anti-β2-GPI antibodies were detected in 21 of 140 patients (15%) and remained positive from 4 to 98 months. Significantly higher incidences of thrombosis, intrauterine fetal loss, thrombocytopenia, patients with antiphospholipid syndrome (APS), prolonged APTT, BFP-STS and hemolytic anemia were found in SLE patients with phospholipid-dependent anti-β2-GPI antibodies. Moreover, significantly lower incidences of malar rash and serositis were found in SLE patients with phospholipid-dependent anti-β2-GPI antibodies, and the majority of these patients satisfied four or five of the revised criteria items of the American Rheumatism Association. These differences were not observed when we compared clinical manifestations in anticardiolipin antibody-positive patients with those in antibody-negative patients by conventional ELISA. These results indicated that SLE patients with IgG phospholipid-dependent anti-β2-GPI antibodies show an unique form of SLE.

Original languageEnglish
Pages (from-to)472-476
Number of pages5
JournalLupus
Volume4
Issue number6
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Systemic Lupus Erythematosus
Phospholipids
Glycoproteins
Antibodies
Immunoglobulin G
Serositis
Enzyme-Linked Immunosorbent Assay
Anticardiolipin Antibodies
Antiphospholipid Syndrome
Hemolytic Anemia
Incidence
Exanthema
Rheumatic Diseases
Thrombocytopenia
Thrombosis
Serum

Keywords

  • Anti-β-glycoprotein I antibodies
  • Anticardiolipin antibodies
  • Antiphospholipid syndrome

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Clinical significance of phospholipid-dependent anti-β2-glycoprotein I(β2-GPI) antibodies in systemic lupus erythematosus. / Kaburaki, J.; Kuwana, M.; Yamamoto, M.; Kawai, S.; Matsuura, Eiji; Ikeda, Y.

In: Lupus, Vol. 4, No. 6, 1995, p. 472-476.

Research output: Contribution to journalArticle

Kaburaki, J, Kuwana, M, Yamamoto, M, Kawai, S, Matsuura, E & Ikeda, Y 1995, 'Clinical significance of phospholipid-dependent anti-β2-glycoprotein I(β2-GPI) antibodies in systemic lupus erythematosus', Lupus, vol. 4, no. 6, pp. 472-476.
Kaburaki, J. ; Kuwana, M. ; Yamamoto, M. ; Kawai, S. ; Matsuura, Eiji ; Ikeda, Y. / Clinical significance of phospholipid-dependent anti-β2-glycoprotein I(β2-GPI) antibodies in systemic lupus erythematosus. In: Lupus. 1995 ; Vol. 4, No. 6. pp. 472-476.
@article{3839f285a9834b4a9aca2d551eca28eb,
title = "Clinical significance of phospholipid-dependent anti-β2-glycoprotein I(β2-GPI) antibodies in systemic lupus erythematosus",
abstract = "We investigated the clinical significance of IgG phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies in patients with SLE. The study population consisted of 140 patients with SLE. Sera were examined for IgG phospholipid-dependent anti-β2-GPI antibodies by ELISA. IgG phospholipid-dependent anti-β2-GPI antibodies were detected in 21 of 140 patients (15{\%}) and remained positive from 4 to 98 months. Significantly higher incidences of thrombosis, intrauterine fetal loss, thrombocytopenia, patients with antiphospholipid syndrome (APS), prolonged APTT, BFP-STS and hemolytic anemia were found in SLE patients with phospholipid-dependent anti-β2-GPI antibodies. Moreover, significantly lower incidences of malar rash and serositis were found in SLE patients with phospholipid-dependent anti-β2-GPI antibodies, and the majority of these patients satisfied four or five of the revised criteria items of the American Rheumatism Association. These differences were not observed when we compared clinical manifestations in anticardiolipin antibody-positive patients with those in antibody-negative patients by conventional ELISA. These results indicated that SLE patients with IgG phospholipid-dependent anti-β2-GPI antibodies show an unique form of SLE.",
keywords = "Anti-β-glycoprotein I antibodies, Anticardiolipin antibodies, Antiphospholipid syndrome",
author = "J. Kaburaki and M. Kuwana and M. Yamamoto and S. Kawai and Eiji Matsuura and Y. Ikeda",
year = "1995",
language = "English",
volume = "4",
pages = "472--476",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Clinical significance of phospholipid-dependent anti-β2-glycoprotein I(β2-GPI) antibodies in systemic lupus erythematosus

AU - Kaburaki, J.

AU - Kuwana, M.

AU - Yamamoto, M.

AU - Kawai, S.

AU - Matsuura, Eiji

AU - Ikeda, Y.

PY - 1995

Y1 - 1995

N2 - We investigated the clinical significance of IgG phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies in patients with SLE. The study population consisted of 140 patients with SLE. Sera were examined for IgG phospholipid-dependent anti-β2-GPI antibodies by ELISA. IgG phospholipid-dependent anti-β2-GPI antibodies were detected in 21 of 140 patients (15%) and remained positive from 4 to 98 months. Significantly higher incidences of thrombosis, intrauterine fetal loss, thrombocytopenia, patients with antiphospholipid syndrome (APS), prolonged APTT, BFP-STS and hemolytic anemia were found in SLE patients with phospholipid-dependent anti-β2-GPI antibodies. Moreover, significantly lower incidences of malar rash and serositis were found in SLE patients with phospholipid-dependent anti-β2-GPI antibodies, and the majority of these patients satisfied four or five of the revised criteria items of the American Rheumatism Association. These differences were not observed when we compared clinical manifestations in anticardiolipin antibody-positive patients with those in antibody-negative patients by conventional ELISA. These results indicated that SLE patients with IgG phospholipid-dependent anti-β2-GPI antibodies show an unique form of SLE.

AB - We investigated the clinical significance of IgG phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies in patients with SLE. The study population consisted of 140 patients with SLE. Sera were examined for IgG phospholipid-dependent anti-β2-GPI antibodies by ELISA. IgG phospholipid-dependent anti-β2-GPI antibodies were detected in 21 of 140 patients (15%) and remained positive from 4 to 98 months. Significantly higher incidences of thrombosis, intrauterine fetal loss, thrombocytopenia, patients with antiphospholipid syndrome (APS), prolonged APTT, BFP-STS and hemolytic anemia were found in SLE patients with phospholipid-dependent anti-β2-GPI antibodies. Moreover, significantly lower incidences of malar rash and serositis were found in SLE patients with phospholipid-dependent anti-β2-GPI antibodies, and the majority of these patients satisfied four or five of the revised criteria items of the American Rheumatism Association. These differences were not observed when we compared clinical manifestations in anticardiolipin antibody-positive patients with those in antibody-negative patients by conventional ELISA. These results indicated that SLE patients with IgG phospholipid-dependent anti-β2-GPI antibodies show an unique form of SLE.

KW - Anti-β-glycoprotein I antibodies

KW - Anticardiolipin antibodies

KW - Antiphospholipid syndrome

UR - http://www.scopus.com/inward/record.url?scp=0029585359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029585359&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 472

EP - 476

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 6

ER -